Title
|
Journal
|
Year
|
|
Phase II study evaluating 2 dosing schedules of oral Foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
|
|
|
|
Analytical performance validation of a coronary heart disease risk assessment multi-analyte proteomic test
|
|
|
|
Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines.
|
|
|
|
Prostaglandin E2: a putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells.
|
|
|
|
Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase 2 study and biomarker analysis with Rilotumumab plus Mitoxantrone and Prednisone.
|
|
|
|
|